Drug Approval | July 06, 2025
Shilpa Pharma Lifesciences Unit-1 inspected by ANVISA
The audit has been concluded with no major observations
The audit has been concluded with no major observations
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The change of name has been carried on pursuant to the Scheme of Amalgamation
This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
The closing of the Block Acquisition is now expected to be completed by Q3 2025
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Subscribe To Our Newsletter & Stay Updated
